GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » Change In Receivables

Icure Pharmaceutical (XKRX:175250) Change In Receivables : ₩-6,961 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical Change In Receivables?

Icure Pharmaceutical's change in receivables for the quarter that ended in Mar. 2025 was ₩-4,076 Mil. It means Icure Pharmaceutical's Accounts Receivable increased by ₩4,076 Mil from Dec. 2024 to Mar. 2025 .

Icure Pharmaceutical's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-3,877 Mil. It means Icure Pharmaceutical's Accounts Receivable increased by ₩3,877 Mil from Dec. 2023 to Dec. 2024 .

Icure Pharmaceutical's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩13,801 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Icure Pharmaceutical's Days Sales Outstanding for the three months ended in Mar. 2025 was 56.91.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Icure Pharmaceutical's liquidation value for the three months ended in Mar. 2025 was ₩-41,390 Mil.


Icure Pharmaceutical Change In Receivables Historical Data

The historical data trend for Icure Pharmaceutical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical Change In Receivables Chart

Icure Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,102.98 6,273.39 658.13 -418.55 -3,876.84

Icure Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -992.41 1,267.05 -1,256.83 -2,894.65 -4,076.43

Icure Pharmaceutical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-6,961 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icure Pharmaceutical  (XKRX:175250) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Icure Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=13801.419/22130.867*91
=56.91

2. In Ben Graham's calculation of liquidation value, Icure Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Icure Pharmaceutical's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6746.975-65508.829+0.75 * 13801.419+0.5 * 14040.843
=-41,390

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icure Pharmaceutical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Icure Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical Headlines

No Headlines